Connor, Clark & Lunn Investment Management Ltd. Biotechnology

Connor, Clark & Lunn Investment Management Ltd.

$20 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
BGNE Bei Gene, Ltd.	$23.5B	$52.5 Million 0.26% of portfolio	284,394	Q4 2024 Added 25.92%
INCY Incyte Corp	$15.7B	$48.6 Million 0.24% of portfolio	704,085	Q4 2024 Added 20.95%
CORT Corcept Therapeutics Inc	$5.93B	$40.2 Million 0.2% of portfolio	796,795	Q4 2024 Reduced 7.3%
MDGL Madrigal Pharmaceuticals, Inc.	$5.67B	$31.9 Million 0.16% of portfolio	103,288	Q4 2024 Added 43.29%
BMRN Biomarin Pharmaceutical Inc	$13.4B	$23.4 Million 0.12% of portfolio	356,496	Q4 2024 Added 206.64%
ZLAB Zai Lab LTD	$3.57B	$22 Million 0.11% of portfolio	841,735	Q4 2024 Added 39.32%
SRPT Sarepta Therapeutics, Inc.	$9.02B	$17.9 Million 0.09% of portfolio	147,236	Q4 2024 Added 88.18%
VKTX Viking Therapeutics, Inc.	$2.23B	$15.1 Million 0.08% of portfolio	375,222	Q4 2024 Added 136.96%
JAZZ Jazz Pharmaceuticals PLC	$8.7B	$13.8 Million 0.07% of portfolio	112,055	Q4 2024 Added 501.38%
ACAD Acadia Pharmaceuticals Inc	$2.84B	$12.6 Million 0.06% of portfolio	685,716	Q4 2024 Reduced 29.5%
BPMC Blueprint Medicines Corp	$5.2B	$12.4 Million 0.06% of portfolio	142,717	Q4 2024 Added 2,680.92%
MNKD Mannkind Corp	$1.28B	$12.2 Million 0.06% of portfolio	1,901,780	Q4 2024 Added 0.87%
VCYT Veracyte, Inc.	$2.29B	$11.1 Million 0.06% of portfolio	279,331	Q4 2024 Reduced 22.6%
RVMD Revolution Medicines, Inc.	$3.44B	$9.12 Million 0.05% of portfolio	208,401	Q4 2024 Added 674.7%
VRTX Vertex Pharmaceuticals Inc	$125B	$8.46 Million 0.04% of portfolio	21,003	Q4 2024 Added 168.2%
TVTX Travere Therapeutics, Inc.	$1.16B	$7.43 Million 0.04% of portfolio	426,726	Q4 2024 Reduced 18.78%
MIRM Mirum Pharmaceuticals, Inc.	$1.6B	$7.32 Million 0.04% of portfolio	176,960	Q4 2024 Added 162.65%
IMVT Immunovant, Inc.	$3.55B	$6.49 Million 0.03% of portfolio	235,884	Q4 2024 Added 29.75%
RNA Avidity Biosciences, Inc.	$1.58B	$6.34 Million 0.03% of portfolio	217,855	Q4 2024 Added 0.38%
AXSM Axsome Therapeutics, Inc.	$5.24B	$6.22 Million 0.03% of portfolio	73,497	Q4 2024 New
UTHR United Therapeutics Corp	$14.4B	$5.13 Million 0.03% of portfolio	14,532	Q4 2024 Added 32.6%
AUPH Aurinia Pharmaceuticals Inc.	$1.16B	$5 Million 0.03% of portfolio	556,454	Q4 2024 Added 22.5%
NVO Novo Nordisk A S	$197B	$4.94 Million 0.02% of portfolio	57,477	Q4 2024 Reduced 10.07%
WVE Wave Life Sciences Ltd.	$816M	$4.8 Million 0.02% of portfolio	387,871	Q4 2024 Added 19.34%
BCRX Biocryst Pharmaceuticals Inc	$1.43B	$4.77 Million 0.02% of portfolio	633,864	Q4 2024 Reduced 7.1%
AMLX Amylyx Pharmaceuticals, Inc.	$227M	$4.76 Million 0.02% of portfolio	1,263,353	Q4 2024 Added 43.44%
IONS Ionis Pharmaceuticals Inc	$4.8B	$4.38 Million 0.02% of portfolio	125,389	Q4 2024 Added 606.78%
AGIO Agios Pharmaceuticals, Inc.	$1.78B	$4.13 Million 0.02% of portfolio	125,678	Q4 2024 Added 464.26%
VNDA Vanda Pharmaceuticals Inc.	$274M	$3.92 Million 0.02% of portfolio	819,382	Q4 2024 Added 4.92%
FOLD Amicus Therapeutics, Inc.	$2.49B	$2.85 Million 0.01% of portfolio	302,536	Q4 2024 Added 35.71%
ETON Eton Pharmaceuticals, Inc.	$369M	$2.83 Million 0.01% of portfolio	214,878	Q4 2024 Added 230.51%
ADMA Adma Biologics, Inc.	$3.34B	$2.81 Million 0.01% of portfolio	163,886	Q4 2024 Reduced 72.17%
CDXC Chroma Dex Corp.	$526M	$2.69 Million 0.01% of portfolio	506,186	Q4 2024 Added 188.97%
SVRA Savara Inc	$297M	$2.57 Million 0.01% of portfolio	837,467	Q4 2024 Added 21.26%
LGND Ligand Pharmaceuticals Inc	$1.94B	$2.55 Million 0.01% of portfolio	23,763	Q4 2024 Reduced 11.87%
MRVI Maravai Lifesciences Holdings, Inc.	$389M	$2.44 Million 0.01% of portfolio	447,994	Q4 2024 Added 14.79%
MGNX Macrogenics Inc	$140M	$2.42 Million 0.01% of portfolio	744,902	Q4 2024 Added 12.54%
HALO Halozyme Therapeutics, Inc.	$8.49B	$1.96 Million 0.01% of portfolio	40,948	Q4 2024 New
AKBA Akebia Therapeutics, Inc.	$349M	$1.91 Million 0.01% of portfolio	1,026,896	Q4 2024 Reduced 1.89%
VTYX Ventyx Biosciences, Inc.	$84.2M	$1.91 Million 0.01% of portfolio	871,527	Q4 2024 Added 88.57%
FULC Fulcrum Therapeutics, Inc.	$163M	$1.73 Million 0.01% of portfolio	367,594	Q4 2024 Added 176.84%
CMRX Chimerix Inc	$739M	$1.49 Million 0.01% of portfolio	429,513	Q4 2024 Added 24.6%
PBYI Puma Biotechnology, Inc.	$160M	$1.49 Million 0.01% of portfolio	487,368	Q4 2024 Added 32.27%
TRDA Entrada Therapeutics, Inc.	$338M	$1.48 Million 0.01% of portfolio	85,621	Q4 2024 Reduced 38.23%
PSTX Poseida Therapeutics, Inc.	$815M	$1.47 Million 0.01% of portfolio	153,058	Q4 2024 Reduced 57.39%
REPL Replimune Group, Inc.	$568M	$1.3 Million 0.01% of portfolio	107,416	Q4 2024 Reduced 16.22%
PRTA Prothena Corp Public LTD CO	$717M	$1.27 Million 0.01% of portfolio	91,840	Q4 2024 Reduced 25.02%
NUVL Nuvalent, Inc.	$3.05B	$1.19 Million 0.01% of portfolio	15,155	Q4 2024 Reduced 55.11%
RARE Ultragenyx Pharmaceutical Inc.	$2.7B	$1.14 Million 0.01% of portfolio	27,016	Q4 2024 Reduced 64.11%
NUVB Nuvation Bio Inc.	$439M	$1.12 Million 0.01% of portfolio	422,260	Q4 2024 Added 6.43%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.